Press Release: Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results

Dow Jones
Nov 16
   -- 33% of evaluable patients demonstrated improvement over baseline in 
      forced vital capacity $(FVC)$ at Week 12 
 
   -- From baseline, change in FVC ranged from an improvement of 338 ml to a 
      decline of 349 ml at Week 12 
 
   -- Low discontinuation rates, and favorable safety and tolerability observed 
      across placebo and treatment groups, with no serious adverse events 
      assessed as related to study treatment 
 
   -- Study has achieved 75% enrollment, with 90 patients randomized to date; 
      on track to report topline data in 2027 

AUSTIN, Texas, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced preliminary blinded twelve-week observations from the ongoing RENEW Phase 2 trial evaluating its lead drug candidate, LTI-03, in patients with idiopathic pulmonary fibrosis (IPF). The Company also reported financial results for the third quarter ended September 30, 2026.

"During the third quarter, we continued to make rapid progress in our Phase 2 RENEW trial for LTI-03 supported by strong enrollment and investigator enthusiasm," said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. "As we continue to enroll patients in the study, today's blinded look at the data shows encouraging lung function trends and a favorable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need. We remain committed to advancing the study toward completion and look forward to reporting unblinded topline data in 2027."

Third Quarter 2026 and Recent Business Updates

Clinical Updates

The RENEW study is a randomized, placebo-controlled Phase 2 trial evaluating inhaled LTI-03 in patients with IPF. The trial remains blinded while enrollment continues. The preliminary analysis included 24 patients with evaluable baseline and Week 12 forced vital capacity (FVC) measurements.

   -- Blinded outcomes consistent with expectations; FVC change at Week 12 
      indicates encouraging distribution: 
 
          -- At Week 12, preliminary blinded lung function observations 
             included: 
 
                 -- 33% of patients (8 of 24) demonstrated an improvement in 
                    FVC from baseline. 
 
                 -- 46% of patients (11 of 24) experienced an FVC decline of no 
                    more than 5.7%, a threshold below which some studies have 
                    indicated a greater than 2X likelihood of progression to 
                    lung transplant or death. 
 
                 -- 21% of patients (5 of 24) experienced an FVC decline in FVC 
                    from baseline of more than 5.7%. 
 
          -- These observations represent pooled results across patients 
             randomized to placebo or one of two LTI-03 dose levels. Treatment 
             assignments remain blinded, and the findings do not establish a 
             treatment effect or allow comparisons between LTI-03 and placebo. 

Figure 1: Blinded, pooled sponsor data (LTI-03 and placebo participants combined). N=24: participants with a Week 12 FVC result. Change in FVC from baseline to Week 12 calculated as a percentage of each participant's own baseline. Baseline was calculated as the mean of the qualifying Screening and Day 1 pre-dose values. Groupings are descriptive and were not pre-specified. These thresholds were used to describe the distribution of blinded, pooled data; they do not predict outcomes for RENEW participants and cannot show a treatment effect. The 5.7% threshold is drawn from an individual participant data meta-analysis of the placebo arms of 12 IPF trial cohorts, in which a relative decline in FVC of more than 5.7% over 3 months was the threshold that best distinguished higher mortality risk (adjusted hazard ratio 2.6; Khan et al., Am J Respir Crit Care Med 2022). At a stricter 5% line, 75% (18 of 24) improved or declined less than 5%. The bar runs from the largest individual gain to the largest individual decline in FVC at Week 12: the full range, not a confidence interval. Not drawn to scale. These are single-participant values and cannot show a treatment effect.

   -- Favorable safety and tolerability profile: 
 
          -- Preliminary blinded safety observations from the ongoing RENEW 
             trial suggest a favorable safety and tolerability profile. 
 
          -- No serious adverse events related to study treatment have been 
             reported as of the interim data cutoff. 
 
          -- Adverse events have been predominantly mild or moderate, with 
             cough representing the most frequently reported adverse event and 
             generally mild in severity. 
 
          -- Low rates of discontinuation, with 92% of enrolled participants 
             remaining on or completing the study. 
 
          -- The trial remains blinded, and treatment-specific safety and 
             tolerability will be further characterized as additional data 
             become available. 
 
   -- On track to report topline data in 2027: As of November, Rein has 
      achieved 75% of the trial's planned enrollment, with 90 out of 
      approximately 120 patients randomized to date across the United States, 
      United Kingdom, Australia, Germany and Poland. Enrollment is tracking 
      ahead of schedule and the Company remains on track to report topline data 
      in 2027. 

"Blinded interim data from our ongoing Phase 2 RENEW trial provides an early look at the safety, tolerability and lung function trends we are observing across the study population. The improvements in FVC from baseline observed in 33% of evaluable patients is particularly encouraging, as improvements in lung function are not expected in this patient population," said Cory Hogaboam, Ph.D., Chief Scientific Officer. "In addition to the lung function improvements we are seeing in the study, adverse events across all patients have been mild to moderate, with no serious adverse events attributable to the drug and low discontinuation rates, with 92% of participants remaining on or completing the study. While the study remains blinded, these observations collectively strengthen our belief that LTI-03 has the potential to transform the treatment landscape for IPF."

Third Quarter 2026 Financial Results

   -- Cash position: Cash, cash equivalents and marketable securities were 
      $36.5 million as of September 30, 2026. The Company's cash, cash 
      equivalents and marketable securities as of September 30, 2026 are 
      expected to fund its operations into the first quarter of 2028 through 
      the completion of the Phase 2 RENEW clinical trial of LTI-03. 
 
   -- R&D expenses: Research and development expenses were $4.4 million for the 
      quarter ended September 30, 2026, compared to $1.7 million for the 
      comparable prior year period. The increase of $2.7 million was primarily 
      due to the increased spending on the RENEW phase 2 clinical trial versus 
      the prior year when the FDA imposed a clinical hold on LTI-03, which was 
      lifted in October 2025. 
 
   -- G&A expenses: General and administrative expenses were $2.6 million for 
      the quarter ended September 30, 2026, compared to $3.8 million for the 
      comparable prior year period. The decrease was primarily due to decreased 
      professional fees. 
 
   -- Net loss: Net loss was $5.5 million for the quarter ended September 30, 
      2026, compared to $5.6 million for the comparable prior year period. 

About LTI-03

LTI-03 is a first-in-class, investigational, inhaled peptide therapy derived from caveolin-1 biology, a key regulator of cellular signaling pathways involved in fibrosis, epithelial injury and tissue repair. LTI-03 is designed to inhibit profibrotic signaling while protecting alveolar epithelial cells that are important for maintaining and repairing lung tissue. The drug's dual mechanism is intended to address both progressive lung scarring and epithelial dysfunction, two important features of IPF. LTI-03 received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration for IPF.

About the Phase 2 RENEW Trial

RENEW is an ongoing randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to evaluate the safety, tolerability and efficacy of inhaled LTI-03 in patients with IPF. The study is expected to enroll approximately 120 patients across clinical sites in the United States, United Kingdom, Australia, Poland, Germany, Bulgaria, and Romania. Participants are randomized to receive one of two LTI-03 dose levels or placebo over a 24-week treatment period. The primary endpoint is safety and tolerability as measured by the incidence of treatment-emergent adverse events. The secondary endpoints are efficacy assessments, including change from baseline in FVC, quantitative high-resolution computed tomography imaging and exploratory biomarkers associated with epithelial injury and fibrosis. The Company expects the trial to remain blinded throughout enrollment and patient follow-up, and to report topline results in 2027. For additional details, please refer to www.clinicaltrials.gov (identifier: NCT06968845).

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the development of LTI-03, the design, conduct and expected results of the Phase 2 RENEW trial, the potential clinical benefits of LTI-03, future development milestones and the Company's financial resources. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: (i) the risk that the Company may not be able to successfully continue its Phase 2 clinical trials of LTI-03; (ii) the risk that the Company may not report topline data derived from its Phase 2 trial in 2027 or, if it does, the risk that the data may not support or validate our expectations concerning the potential benefits of LTI-03; (iii) success in early phases of pre-clinical and clinical trials do not ensure later clinical trials will be successful; (iv) the risk that preliminary blinded interim observations may not predict subsequent or final study results; (v) the fact that the lung function observations described in this release are pooled across randomized treatment groups and cannot establish efficacy, dose response or superiority to placebo; (vi) the fact that the 5.7% FVC decline threshold is descriptive and is not a validated Week-12 measure of treatment response; (vii) the fact that preliminary adverse-event causality assessments may change as additional data become available; and (viii) the risk that the Company's present cash and cash equivalents may not be sufficient to fund the Company's operations into the first quarter of 2028 and (v) those other risks disclosed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 26, 2026, and in subsequent filings that the Company makes with the SEC. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Rein Therapeutics Investor Relations & Media Contact:

Investor Relations

IR@ReinTx.com

 
                        REIN THERAPEUTICS, INC. 
                  CONDENSED CONSOLIDATED BALANCE SHEETS 
                               (UNAUDITED) 
             (In thousands, except share and per share data) 
 
                                      September 30,     December 31, 
                                           2026             2025 
                                     ---------------   -------------- 
Assets 
Current assets: 
   Cash and cash equivalents          $          943    $       3,215 
   Short-term investments                     34,550               -- 
   Prepaid expenses and other 
    current assets                             1,292            1,111 
                                         -----------       ---------- 
     Total current assets                     36,785            4,326 
Goodwill                                       6,330            6,330 
Intangible assets                             13,500           13,500 
Long-term investments                            994               -- 
Other non-current assets                       1,821                2 
                                         -----------       ---------- 
     Total assets                     $       59,430    $      24,158 
                                         ===========       ========== 
Liabilities, Convertible Preferred 
Stock and Stockholders' Equity 
Current liabilities: 
   Accounts payable                   $        3,199    $       3,976 
   Accrued expenses and other 
    current liabilities                        2,399            2,204 
     Total current liabilities                 5,598            6,180 
Deferred tax liability                         1,060            1,060 
                                         -----------       ---------- 
     Total liabilities                         6,658            7,240 
                                         -----------       ---------- 
Commitments and contingencies 
(Note 13) 
Convertible preferred stock, $0.001 
 par value, 5,000,000 shares 
 authorized at September 30, 2026 
 and at December 31, 2025; 24,610 
 shares issued and 12,232 shares 
 outstanding at September 30, 2026 
 and at December 31, 2025                     45,005           45,005 
Stockholders' equity: 
   Common stock, $0.001 par value; 
    200,000,000 shares and 
    100,000,000 authorized at 
    September 30, 2026 and at 
    December 31, 2025, 
    respectively; 86,267,032 shares 
    and 27,550,222 shares issued 
    and outstanding at September 
    30, 2026 and at December 31, 
    2025, respectively                           172              113 
   Additional paid-in capital                426,731          373,133 
   Accumulated other comprehensive 
    loss                                        (115)             (62) 
   Accumulated deficit                      (419,021)        (401,271) 
                                         -----------       ---------- 
     Total liabilities, convertible 
      preferred stock and 
      stockholders' equity            $       59,430    $      24,158 
                                         ===========       ========== 
 
 
 
                           REIN THERAPEUTICS, INC. 
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND 
                              COMPREHENSIVE LOSS 
                                  (UNAUDITED) 
                (In thousands, except share and per share data) 
 
                         Three Months Ended           Nine Months Ended 
                            September 30,               September 30, 
                      -------------------------   ------------------------- 
                         2026          2025          2026          2025 
                      -----------   -----------   -----------   ----------- 
Revenue               $    --       $    --       $    --       $    -- 
                       ----------    ----------    ----------    ---------- 
Operating expenses: 
   Research and 
    development             4,375         1,681        11,086         9,028 
   General and 
    administrative          2,624         3,811         7,219         8,944 
     Total operating 
      expenses              6,999         5,492        18,305        17,972 
                       ----------    ----------    ----------    ---------- 
Loss from operations       (6,999)       (5,492)      (18,305)      (17,972) 
Other (expense) 
 income, net                1,462           (89)          555            68 
Net loss              $    (5,537)  $    (5,581)  $   (17,750)  $   (17,904) 
                       ==========    ==========    ==========    ========== 
Net loss per 
 share--basic and 
 diluted              $     (0.06)  $     (0.21)  $     (0.29)  $     (0.74) 
                       ==========    ==========    ==========    ========== 
Weighted average 
 common shares 
 outstanding--basic 
 and diluted           88,325,917    26,361,386    62,134,091    24,171,173 
                       ==========    ==========    ==========    ========== 
Comprehensive loss: 
Net loss              $    (5,537)  $    (5,581)  $   (17,750)  $   (17,904) 
Other comprehensive 
loss: 
   Unrealized (loss) 
    gain on 
    investments, net 
    of tax of $0              (45)           --           (57)          (33) 
   Foreign currency 
    translation 
    adjustments                (1)           --             4             7 
                       ----------    ----------    ----------    ---------- 
     Total other 
      comprehensive 
      loss                    (46)           --           (53)          (26) 
                       ----------    ----------    ----------    ---------- 
Total comprehensive 
 loss                 $    (5,583)  $    (5,581)  $   (17,803)  $   (17,930) 
                       ==========    ==========    ==========    ========== 
 
 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/22b5e69b-3a1b-4989-b1a9-5cc386743bf1

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10